Denosumab for the Treatment of Adult LCH

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 7, 2017

Primary Completion Date

June 22, 2022

Study Completion Date

January 14, 2025

Conditions

Langerhans Cell Histiocytosis

Interventions

DRUG

Denosumab 70 MG/ML [Xgeva]

As already described in arm description

Trial Locations (1)

251 Hellenic AirForce & VA General Hospital, Dpt of Endocrinology, Athens

All Listed Sponsors

lead

Hellenic Society for the Study of Bone Metabolism

OTHER

NCT03270020 - Denosumab for the Treatment of Adult LCH | Biotech Hunter | Biotech Hunter